Swiss LithoClast® Trilogy Lithotripter

Swiss LithoClast® Trilogy Lithotripter – The Ultimate Dual-Energy Stone Management System for Precision, Power, and Efficiency

Transform your lithotripsy procedures with the Swiss LithoClast® Trilogy, the industry-leading dual-energy, single-probe lithotripter that redefines speed, safety, and control in percutaneous nephrolithotomy (PCNL) and beyond.

Unparalleled Efficiency: Faster Stone Clearance, Shorter Procedures

Accelerated fragmentation and removal: Bench studies show the Swiss LithoClast® Trilogy clears stones up to 48% faster than prominent dual-energy.

In observational clinical settings, lithotripsy and stone removal account for roughly 30% of total PCNL procedural time—around 24 minutes in the U.S.—highlighting how crucial speed truly is.

Dynamic Power: Combined Ultrasonic, Ballistic Energy & Suction, All from One Probe

Simultaneous or independent energy delivery: Designed with a proprietary electromagnetic propulsion system, the Trilogy delivers controlled ballistic and ultrasonic energy—alone or together—with integrated suction, maximizing effectiveness against all types of stones.

Superior fragmentation power: The ballistics feature up to 25× greater probe tip movement.

Efficient aspiration of large fragments: The wider hollow-lumen probe design enhances removal rates via powerful suction.

Easy, Intuitive Operation: Streamlined Setup & Ergonomic Design

Plug-and-play console: No need for external compressors or suction pumps—one console fits all.

Rapid assembly: Few components, quick setup, and torque-wrench probe tightening for effortless preparation.

Smart probe recognition: Contactless RFID recognition automatically calibrates energy for each probe, saving valuable OR time.

User-friendly interface: A large touchscreen and quality monitor provide intuitive visualization and control of energy and fragmentation settings.

Safe & Controlled: Precision Stone Management Meets Clinical Confidence

Minimized retropulsion: Ballistic probe tip displacements are up to 8× smaller than traditional pneumatic systems, reducing retropulsion and conferring superior control.

Advanced suction control: Integrated suction activates only during treatment, reducing unintended tissue trauma and optimizing stone removal.

Active cooling: The handpiece includes cooling technology for operator comfort and enhanced system durability.

Data traceability: RFID tagging records treatment parameters, tracks component usage, and facilitates diagnostics for streamlined maintenance and regulatory compliance.

Versatility & Clinical Validation: Adaptable Across Techniques with Proven Outcomes

Wide probe selection: Compatibility extends from standard 30 FR/24 FR PCNL to Mini-PCNL, semi-rigid ureteroscopy, and cystoscopy options.

Clinician-approved efficacy: A European multicenter prospective study involving 157 cases reported a post-operative stone-free rate of 88%, with Trilogy proving nearly twice as effective in stone removal than previously documented devices.

International endorsements: Urology leaders, such as Dr. Janak Desai and Dr. Oliver Wiseman, praise its comprehensive stone management capabilities—from breaking stones cleanly to effortlessly evacuating fragments.

Why Swiss LithoClast® Trilogy is a Game-Changer for Urology Practices

Maximize OR efficiency: Spend less time on stone removal and more on patient care, thanks to superior fragmentation speed and integrated suction.

Elevate surgical control: Significantly reduce stone retropulsion and gain precise energy modulation—all via a single ergonomic probe.

Simplify workflows: Intuitive setup, smart probe calibration, and touchscreen guidance streamline staff training and procedural execution.

Deliver safer outcomes: Active cooling, controlled suction, and built-in diagnostics ensure consistent performance and patient safety.

Adapt easily: Compatible probes across a range of urologic procedures cater to diverse clinical needs, including mini-PCNL and ureteroscopy.

Evidence-based confidence: Proven efficacy and high stone-free rates in multicenter studies affirm its clinical superiority.